NasdaqCM:VSTMBiotechs
Verastem (VSTM) Q4 Revenue Reaches US$17.5 Million Yet Heavy Losses Reinforce Bearish Views
Verastem (VSTM) closed FY 2025 with fourth quarter revenue of US$17.5 million and a basic EPS loss of US$0.39, alongside a net loss of US$32.9 million. This put hard numbers around a year that also produced trailing twelve month revenue of US$30.9 million and a basic EPS loss of US$3.02. Across the FY 2025 quarters, the company reported revenue of US$0 in Q1, US$2.1 million in Q2, US$11.2 million in Q3 and US$17.5 million in Q4, while quarterly EPS losses ranged between US$0.39 and US$1.35...